CDE Detailed Report
Disease: content
Subdomain Name: Epidemiology/Environmental History
CRF: welcome
Displaying 1 - 19 of 19
Subdomain Name: Epidemiology/Environmental History
CRF: welcome
Displaying 1 - 19 of 19
| CDE ID | CDE Name | Variable Name | Definition | Short Description | Question Text | Permissible Values | Description | Data Type | Disease Specific Instructions | Disease Specific Reference | Population | Classification (e.g., Core) | Version Number | Version Date | CRF Name (CRF Module / Guidance) | Subdomain Name | Domain Name | Size | Input Restrictions | Min Value | Max Value | Measurement Type | External Id Loinc | External Id Snomed | External Id caDSR | External Id CDISC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C17683 | Non-prescribed controlled psychoactive drug substance marijuana text | NprscrbContrPschacDrgSbMrjTxt | The text specifying the drugs within the Marijuana: hash, THC category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the Marijuana: hash, THC category as unprescribed, controlled psychoactive drugs or substances used by the participant/subjec |
Marijuana: (hash, THC, or grass) List |
Alphanumeric |
For each class of drug, list specific drug(s) used. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 11:44:17.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C59023 | Non-prescribed controlled psychoactive drug substance anti-psychotic text | NprscrCntrPschacDrgSbAntpsyTxt | The text specifying the drugs within the 'Anti-psychotics: (Thorazine or Haldol)' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'Anti-psychotics: (Thorazine or Haldol)' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject |
Anti-psychotics: (Thorazine or Haldol) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 1.00 | 2022-06-24 12:19:43.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C17684 | Non-prescribed controlled psychoactive drug substance stimulant cocaine text | NprscrCntrPschacDrgSbStmCocTxt | The text specifying the drugs within the Stimulants: cocaine/crack category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the Stimulants: cocaine/crack category as unprescribed, controlled psychoactive drugs or substances used by the participant/subjec |
Cocaine or crack List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 11:48:57.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C59024 | Subscribed drug or substance illicitly used specify other text | SbscrbdDrgSubIllctUseSpcfyOTH | The text specifying the drugs within the 'Other, specify: (e.g., anabolic steroids)' category as illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in large amounts | The text specifying the drugs within the 'Other, specify: (e.g., anabolic steroids)' category as illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in l |
Other, specify: (e.g., anabolic steroids) List |
Alphanumeric |
For each class of drug, list specific drug(s) used. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 1.00 | 2022-06-24 12:21:47.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 4000 |
Free-Form Entry |
|||||||||
| C17685 | Non-prescribed controlled psychoactive drug substance stimulant amphetamine text | NprscrCntrPschacDrgSbStmAmpTxt | The text specifying the drugs within the 'Stimulants: amphetamine, Benzedrine, Methedrine, Dexedrine, Preludin, Ritalin, uppers, speed,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'Stimulants: amphetamine, Benzedrine, Methedrine, Dexedrine, Preludin, Ritalin, uppers, speed,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subjec |
Stimulants: (Crystal Meth, uppers, or speed) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 11:53:43.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C17686 | Non-prescribed controlled psychoactive drug substance sedative tranquilizer text | NprscrCntrPschacDrgSbSedTrnTxt | The text specifying the drugs within the 'Sedatives/minor tranquilizers/muscle relaxants-benzodiazepines and others: Valium/diazepam, Librium, Halcion, Xanax, Dalmane, Flexeril,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'Sedatives/minor tranquilizers/muscle relaxants-benzodiazepines and others: Valium/diazepam, Librium, Halcion, Xanax, Dalmane, Flexeril,' category as unprescribed, controlled psychoactive drugs or substances us |
Anti-anxiety drugs: (Valium®, Librium, muscle relaxants, or Xanax) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 12:01:23.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C17687 | Non-prescribed controlled psychoactive drug substance sedative barbiturate text | NprscrCntrPschacDrgSbSedBrbTxt | The text specifying the drugs within the 'Sedatives-barbiturates and others: phenobarbital, Seconol, Nembutal, Dorieden, Quaalude, Amytal, Fiorinal, downers,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | Text specifying the drugs within the 'Sedatives-barbiturates and others: phenobarbital, Seconol, Nembutal, Dorieden, Quaalude, Amytal, Fiorinal, downers,' category as unprescribed, controlled psychoactive drugs or substances used by the participant |
Sedatives: (sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 12:07:04.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C00712 | Subscribed drug or substance illicitly used category | SbscrbdDrgSubIllctUseCat | Category of illegal drugs, prescription, or over-the-counter drugs subscribed by the participant/subject, and used for purposes other than those for which they are meant to be used, or in large amounts | Category of illegal drugs, prescription, or over-the-counter drugs subscribed by the participant/subject, and used for purposes other than those for which they are meant to be used, or in large amounts | Drug Class | Marijuana (hash, THC, or grass);Cocaine or crack;CBD (Cannabidiol);Stimulants (Crystal Meth, uppers, or speed);Anti-anxiety drugs (Valium, Librium, muscle relaxants, or Xanax);Opioids (Codeine, Fentanyl, Oxycontin, Darvon, Percodan, Dilaudid, or Demerol);Sedatives (e.g., sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate);Inhalants or Solvents (e.g., amyl nitrate, nitrous oxide, glue, toluene, or gasoline;Heroin;Hallucinogens (Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, ketamine, or peyote);L-Dopa supplements;Anti-psychotics (Thorazine or Haldol);Other, specify (e.g., anabolic steroids) | Marijuana (hash, THC, or grass);Cocaine or crack;CBD (Cannabidiol);Stimulants (Crystal Meth, uppers, or speed);Anti-anxiety drugs (Valium, Librium, muscle relaxants, or Xanax);Opioids (Codeine, Fentanyl, Oxycontin, Darvon, Percodan, Dilaudid, or Demerol);Sedatives (e.g., sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate);Inhalants or Solvents (e.g., amyl nitrate, nitrous oxide, glue, toluene, or gasoline;Heroin;Hallucinogens (Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, ketamine, or peyote);L-Dopa supplements;Anti-psychotics (Thorazine or Haldol);Other, specify (e.g., anabolic steroids) | Alphanumeric |
Enter information about the use of any of the types of drugs listed. Include drugs used at any time in life, but do not include any drugs prescribed by a doctor. Examples and common names are given for each class of drug. For each class of drug, list specific drug(s) used. If a class of drug was never used (except if prescribed), then leave years and frequency of use blank and go to the next line in the table |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult;Pediatric | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History |
Multiple Pre-Defined Values Selected |
3171797 | |||||||
| C17688 | Non-prescribed controlled psychoactive drug substance opioid text | NprscrCntrPschacDrgSbOpioidTxt | The text specifying the drugs within the 'Opioids/Narcotics: heroin, opium, morphine, methadone, codeine, Darvon, Percodan, Oxycontin, Dilaudid, Demerol/meperidine,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the Opioids/Narcotic: heroin, opium, morphine, methadone, codeine, Darvon, Percodan, Oxycontin, Dilaudid, Demerol/meperidine category as unprescribed, controlled psychoactive drugs or substances used by the participant |
Opioids: (Codeine, Fentanyl, Oxycontin, Darvon, Percodan, Dilaudid, or Demerol) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 4.00 | 2022-06-24 12:09:24.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C00716 | Drug or substance illicit use duration | DrgSubsIllctUseDur | Duration, in years, the participant/subject has used unprescribed, controlled psychoactive drugs or substances | Duration, in years, the participant/subject has used unprescribed, controlled psychoactive drugs or substance | Total Years Used | Numeric Values |
Count only number of years in which some use occurred. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History |
Free-Form Entry |
0 | 99 | Year | 2004152 | ||||||
| C17689 | Non-prescribed controlled psychoactive drug substance inhalant text | NprscrCntrPschacDrgSbInhlntTxt | The text specifying the drugs within the 'Inhalants: glue, toluene, gasoline, aerosols, paint thinner, nitrous oxide, amyl nitrite,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'Inhalants: glue, toluene, gasoline, aerosols, paint thinner, nitrous oxide, amyl nitrite,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject |
Inhalants or Solvents: (amyl nitrate, nitrous oxide, glue, toluene, or gasoline) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 12:15:36.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C08232 | Drug or substance illicit use ever indicator | DrgSubIllicitEverUseInd | Indicator of participant's/subject's use of illegal drugs, prescription or over-the-counter drugs at any point in his/her lifetime for purposes other than those for which they are meant to be used, or in large amounts | Indicator of participant's/subject's use of an unprescribed, controlled psychoactive drugs or substances used by the participant/subject. at any point in his/her lifetime | Ever Used? | Yes;No;Unknown | Yes;No;Unknown | Alphanumeric |
Enter information about the use of any of the types of drugs. Include drugs used at any time in life, but do not include any drugs prescribed by a doctor. Examples and common names are given for each class of drug. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History |
Single Pre-Defined Value Selected |
||||||||
| C17690 | Non-prescribed controlled psychoactive drug substance hallucinogen text | NprscrCntrPschacDrgSbHalcnTxt | The text specifying the drugs within the 'Hallucinogens: ecstasy/MDMA, LSD, mescaline/peyote, psilocybin/mushrooms, PCP/phencylidine/angel dust, MDA/STP/DOM,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | Text specifying the drugs within the 'Hallucinogens: ecstasy/MDMA, LSD, mescaline/peyote, psilocybin/mushrooms, PCP/phencylidine/angel dust, MDA/STP/DOM,' category as unprescribed, controlled psychoactive drugs or substances used by the participant |
Hallucinogens: (Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, ketamine, or peyote) List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.10 | 2022-06-24 12:17:25.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C08233 | Drug or substance first illicit use date and time | DrgSubFirstIllicitUseDateTime | Date (and time if applicable and known) the participant/subject first used the category of illegal drugs, prescription or over-the-counter drugs | Date (and time if applicable and known) the participant/subject first used the category of illegal drugs, prescription or over-the-counter drug | Year First Used | Date or Date & Time |
Enter information about the use of any of the types of drugs listed. Include drugs used at any time in life, but do not include any drugs prescribed by a doctor. Examples and common names are given for each class of drug. If a class of drug was never used (except if prescribed), then leave years and frequency of use blank and go to the next line in the table. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History |
Free-Form Entry |
||||||||||
| C18670 | Subscribed drug or substance illicitly used category other text | SbscrbdDrgSubIllctUseCatOTH | The free-text field related to 'Subscribed drug or substance illicitly used category' specifying other text. Category of illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in large amounts | Subscribed drug substance illicitly used category specifying other text. Category of illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in large amounts | Other, specify: (e.g., anabolic steroids) | Alphanumeric |
Enter information about the use of any of the types of drugs listed. Include drugs used at any time in life, but do not include any drugs prescribed by a doctor. Examples and common names are given for each class of drug. For each class of drug, list specific drug(s) used. If a class of drug was never used (except if prescribed), then leave years and frequency of use blank and go to the next line in the table. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 1.10 | 2022-06-24 11:33:13.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 4000 |
Free-Form Entry |
3171797 | ||||||||
| C08234 | Drug or substance last illicit use date and time | DrgSubLastIllicitUseDateTime | Date (and time if applicable and known) of the participant's/subject's last use of an unprescribed, controlled psychoactive drugs or substances used by the participant/subject | Date (and time if applicable and known) of the participant's/subject's last use of an unprescribed, controlled psychoactive drugs or substances used by the participant/subjec | Year Last Used | Date or Date & Time |
Enter information about the use of any of the types of drugs listed. Include drugs used at any time in life, but do not include any drugs prescribed by a doctor. Examples and common names are given for each class of drug. If a class of drug was never used (except if prescribed), then leave years and frequency of use blank and go to the next line in the table. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History |
Free-Form Entry |
||||||||||
| C59021 | Non-prescribed controlled psychoactive drug substance heroin text | NprscrCntrPschacDrgSbHeroinTxt | The text specifying the drugs within the 'Heroin' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'Heroin' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject |
Heroin List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 1.00 | 2022-06-24 12:11:26.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C08235 | Drug or substance illicit use frequency | DrgSubIllicitUseFreq | The subject's/participant's average or typical use frequency during the year of greatest use of an unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The subject's/participant's average or typical use frequency during the year of greatest use of an unprescribed, controlled psychoactive drugs or substances used by the participant/subjec | Frequency of Use | Alphanumeric |
Average or typical frequency during the year of greatest use. List number of uses per day (_/d), week (_/w), month (_/m), or year (_/y), as applicable. |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 3.00 | 2013-07-22 09:34:41.527 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
|||||||||
| C59022 | Non-prescribed controlled psychoactive drug substance L-Dopa supplement text | NprscrCntrPschacDrgSbLDpaSpTxt | The text specifying the drugs within the 'L-Dopa supplements' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject | The text specifying the drugs within the 'L-Dopa supplements' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject |
L-Dopa supplements List |
Alphanumeric |
For each class of drug, list specific drug(s) used |
Ferreira C, Almeida C, Tenreiro S, Quintas A. Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. Life (Basel). 2020 Jun 11;10(6):86.<br /><br />Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018 Jun 1;187:134-140. | Adult | Supplemental | 1.00 | 2022-06-24 12:17:43.0 | Non-prescribed Drug Use Questionnaire | Epidemiology/Environmental History | Participant History and Family History | 255 |
Free-Form Entry |
